Physician profile
Cindy D Mann
NPI 1467793091
$1,161.91
in general payments reported to CMS, 2019-2025
17 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $115 · 2023: $160 · 2024: $186 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.10 | 2021-2025 | Wegovy |
| Abbvie INC. | $178.03 | 2021-2025 | |
| Amarin Pharma, INC. | $128.35 | 2021 | |
| Aimmune Therapeutics, INC. | $125.00 | 2024 | |
| Gilead Sciences, INC. | $112.35 | 2025 | Epclusa |
| Biohaven Pharmaceuticals, INC. | $68.60 | 2021 | |
| Pfizer INC. | $56.57 | 2023 | |
| Lilly USA, LLC | $56.04 | 2021-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $50.91 | 2021-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $37.42 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $36.57 | 2021 | |
| Esperion Therapeutics, INC. | $28.93 | 2021 | |
| Abbott Laboratories | $22.52 | 2021 | |
| Sandoz INC. | $15.12 | 2023 | Hyrimoz |
| Optinose US, INC. | $13.84 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $13.43 | 2023 | Liberty Select Cycler |
| Ultragenyx Pharmaceutical INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.